| % positive cases (n = 51) | BC007/BC-P007MT1 | BC107/BC-P107MT1 | BC515/BC-P515MT1 | BC877/BC-P877MT1 | HS-5 | |
---|---|---|---|---|---|---|---|
(% positive cells) | |||||||
MSC marker | CD44 | 68.6% | 50/60 | 60/30 | -/- | -/- | + |
CD29 | 27.4% | 10/40 | <5/30 | 5/<1 | -/- | + | |
CD166 | 78.4% | <5/< 5 | 10/50 | 5/5 | 90/90 | + | |
CDI06 | 29.4% | 30/<10 | <10/<10 | -/- | 80/80 | + | |
CD105 | 1.9% | -/- | -/- | -/- | 50/90 | + | |
CD90 | 78.4% | <10/< 10 | 10/10 | 55/75 | <5/70 | + | |
CD117 | 70.5% | -/20 | -/- | 5/50 | 80/95 | + | |
GD2 | 100% | 80/50 | 75/30 | 90/75 | 60/30 | + | |
(<10 to >90) | Â | Â | Â | Â | Â | ||
Stem cell marker | ALDH | 100% | 20/1 | 3-5/<1 | 40/5 | <1/<5 | + |
(<10 to >90) | Â | Â | Â | Â | Â | ||
Oct-4 | 47.0% | 10/5 | 30/10 | <1/35 | <5/<5 | + | |
PT clinically relevant markers | Vimentin | 100% | 90/ > 90 | 90/>70 | 80/20 | >95/>95 | + |
(<10- to >90) | Â | Â | Â | Â | Â | ||
Ki-67 | 82.3% | 40/40 | 10/20 | 5/<3 | 65/>95 | + | |
CD10 | 60.7% | 20/5 | 10/70 | 5/5 | <10/30 | + | |
CD34 | 52.9% | -/- | 40/70 | 80/20 | -/- | - | |
p53 | 50.9% | <10/<10 | <5/10 | 70/60 | >95/>95 | + | |
Bcl-2 | 37.2% | -/- | -/- | -/- | -/- | - | |
p63 | 9.8% | 60/10 | -/- | -/- | -/- | - | |
Globo-H | 9.8% | -/- | -/- | -/- | 80/80 | - |